Xenetic Biosciences Inc (NASDAQ:XBIO) Short Interest Up 460.0% in October

Xenetic Biosciences Inc (NASDAQ:XBIO) was the target of a significant increase in short interest in October. As of October 15th, there was short interest totalling 16,800 shares, an increase of 460.0% from the September 30th total of 3,000 shares. Based on an average trading volume of 16,800 shares, the days-to-cover ratio is presently 1.0 days. Approximately 1.3% of the shares of the stock are short sold.

Analysts Set New Price Targets

Separately, HC Wainwright reissued a “neutral” rating on shares of Xenetic Biosciences in a research note on Tuesday, August 20th.

Xenetic Biosciences Trading Up 2.8 %

Shares of NASDAQ XBIO traded up $0.10 during trading hours on Friday, reaching $3.70. The stock had a trading volume of 10,303 shares, compared to its average volume of 9,308. The firm has a 50-day moving average of $3.92 and a 200-day moving average of $3.96. The firm has a market cap of $5.70 million, a price-to-earnings ratio of -1.26 and a beta of 2.25. Xenetic Biosciences has a fifty-two week low of $2.78 and a fifty-two week high of $5.20.

Xenetic Biosciences (NASDAQ:XBIO) last issued its earnings results on Tuesday, August 13th. The company reported ($0.83) earnings per share for the quarter, hitting the consensus estimate of ($0.83). The company had revenue of $0.73 million for the quarter, compared to analyst estimates of $0.54 million. Xenetic Biosciences had a negative net margin of 186.39% and a negative return on equity of 51.05%. On average, equities analysts predict that Xenetic Biosciences will post -1.01 EPS for the current year.

About Xenetic Biosciences

Xenetic Biosciences, Inc is a biopharmaceutical company focused on progressing XCART, a personalized CAR T platform technology engineered to target patient-specific tumor neoantigens. The Company is initially advancing cell-based therapeutics targeting the unique B-cell receptor on the surface of an individual patient’s malignant tumor cells for the treatment of B-cell lymphomas.